Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
|Videos|May 12, 2017
Treatment of Malignant Melanoma
Treatment of Malignant Melanoma
Advertisement
- A 46-year-old Caucasian female presented one year ago with deep ulcerated primary tumor and multiple involved lymph nodes.
- She was diagnosed with stage IIIC melanoma.
- Patient underwent wide local incision and compete lymph node dissection and appeared to be clear of disease.
- Patient decided not to pursue adjuvant therapy after surgery.
- Six months after surgery, she developed abdominal pain.
- Imaging showed multiple masses in the liver, > 1 cm, scattered pulmonary nodules and some enlarged lymph nodes.
- Tumor biopsy confirmed melanoma and mutational analysis showed BRAF V600E mutation.
- The patient is started on dabrafenib 150 mg bid and trametinib 2 mg qd.
Advertisement
Related to this article
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
2
FDA Approves Generic Venetoclax Tablets for CLL/SLL and AML
3
Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer
4
Neoadjuvant Botensilimab/Balstilimab Shows Activity in Colon Cancer
5